Is Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?

Drugs in R and D - United Kingdom
doi 10.1007/s40268-018-0254-8
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN)

Therapeutic Drug Monitoring
Pharmacology
2019English

Conversion of Liver Transplant Recipients on Cyclosporine With Renal Impairment to Mycophenolate Mofetil

Liver Transplantation and Surgery
1999English

Prospects for Using Mycophenolate Mofetil in Diffuse Scleroderma

Modern Rheumatology Journal
2009English

Mycophenolate Mofetil for Drug-Induced Vanishing Bile Duct Syndrome

World Journal of Gastroenterology
MedicineGastroenterology
2007English

Cyclophosphamide Versus Mycophenolate Mofetil for Initial Treatment of Lupus Nephritis

Kidney International
Nephrology
2013English

Vancomycin Relieves Mycophenolate Mofetil–induced Gastrointestinal Toxicity by Eliminating Gut Bacterial Β-Glucuronidase Activity

Science advances
Multidisciplinary
2019English

Mycophenolate Mofetil for Myasthenia Gravis: An Open-Label Pilot Study

Neurology
Neurology
2001English

Enteric-Coated Mycophenolate Sodium Can Be Safely Administered in Maintenance Renal Transplant Patients: Results of a 1-Year Study

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2004English

Low Dose of Mycophenolate Mofetil Is Enough in Desensitized Kidney Transplantation Using Rituximab

BMC Nephrology
Nephrology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy